Axogen Inc (AXGN) Stock Price, Quote & News

Company Profile

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wra...

Industry: Medical Devices

Sector: Healthcare

Phone: 386 462 6800

Fax: 386 462 6801

Website: www.axogeninc.com

Address:

13631 Progress Boulevard, Suite 400, Alachua, United States

RunnerSignals Apr. 25 at 6:12 AM

$CLSK $AMX $AXGN $INDI $SLM 3d streaks +3–7.6%, vol 1.3–3.1x, rsi high-60s

0 · Reply

dustin1101 Apr. 24 at 2:32 PM

$AXGN No significant sellers, buyers lurking. Likely coils up at ~$39 and then smashes into the $40’s. GL shorty 🤑

0 · Reply

dustin1101 Apr. 24 at 1:47 PM

$AXGN Cannacord $40 >>> $45 pt today.. sleepy stock open let's goooo!

0 · Reply

dustin1101 Apr. 23 at 2:54 PM

$AXGN just loaded back in 36.94. 2K shares. Lake Street $40 >>>$50 pt today. Still wary of mkt but ER next week...

0 · Reply

dustin1101 Apr. 22 at 4:53 PM

$AXGN selling back some over $37 since the mkt seems like it could roll over here. Not a lot of sellers though.

0 · Reply

dustin1101 Apr. 21 at 9:12 PM

$AXGN there you have it.. Easy reload on the pullback. Added 36.50 and 36.04 today. More powder available if needed.

0 · Reply

dustin1101 Apr. 20 at 2:23 PM

$AXGN Have to figure it checks out the $36-37 range again, barring another catalyst.

0 · Reply

dustin1101 Apr. 17 at 6:15 PM

$AXGN Sold some as high as 39.95. Was hoping we’d see an afternoon rally to highs but it doesn’t look like the mkt will support it. Could be wrong, crazy action out there. Flipped out about 1/4 of position and ready to add on pullback if it happens. Still LT

0 · Reply

dustin1101 Apr. 17 at 1:37 PM

$AXGN Can't say I didn't just warn them.. 😂🤑

0 · Reply

WAJeff Apr. 17 at 1:33 PM

$AXGN $39 52 week high

0 · Reply

Axogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026

Feb 17, 2026, 7:00 AM EST - 2 months ago

Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences

Feb 10, 2026, 7:00 AM EST - 2 months ago

Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Jan 21, 2026, 11:18 PM EST - 3 months ago

Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock

Jan 21, 2026, 4:09 PM EST - 3 months ago

Axogen Announces Proposed Public Offering of Common Stock

Jan 12, 2026, 7:00 AM EST - 3 months ago

Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025

Dec 3, 2025, 8:01 PM EST - 5 months ago

Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)

Dec 3, 2025, 6:53 PM EST - 5 months ago

FDA approves Axogen's nerve repair graft

Oct 29, 2025, 7:00 AM EDT - 6 months ago

Axogen, Inc. Reports Third Quarter 2025 Financial Results

Oct 1, 2025, 12:30 PM EDT - 7 months ago

Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN

Oct 1, 2025, 10:50 AM EDT - 7 months ago

AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm

Aug 25, 2025, 6:40 AM EDT - 8 months ago

Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft

Jul 29, 2025, 4:10 PM EDT - 9 months ago

Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference

Jul 22, 2025, 4:05 PM EDT - 9 months ago

Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025

May 28, 2025, 8:00 AM EDT - 11 months ago

Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference

May 8, 2025, 7:05 AM EDT - 1 year ago

Axogen, Inc. Reports 2025 First Quarter Financial Results

Apr 24, 2025, 8:04 AM EDT - 1 year ago

Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025

Feb 25, 2025, 7:10 AM EST - 1 year ago

Axogen, Inc. To Host Analyst & Investor Day on March 4th

Feb 11, 2025, 4:58 PM EST - 1 year ago

Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025

Jan 10, 2025, 5:00 PM EST - 1 year ago

Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sep 6, 2024, 7:00 AM EDT - 1 year ago

Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®

Aug 8, 2024, 7:05 AM EDT - 1 year ago

Axogen, Inc. Announces New Leadership Appointments

Jul 23, 2024, 7:00 AM EDT - 1 year ago

Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

Jul 1, 2024, 7:00 AM EDT - 1 year ago

Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™

May 28, 2024, 4:30 PM EDT - 2 years ago

Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia

May 2, 2024, 7:00 AM EDT - 2 years ago

Axogen, Inc Reports First Quarter 2024 Financial Results

Apr 29, 2024, 4:50 PM EDT - 2 years ago

Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™

Apr 16, 2024, 7:00 AM EDT - 2 years ago

Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

Mar 5, 2024, 7:00 AM EST - 2 years ago

Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results

Feb 13, 2024, 4:30 PM EST - 2 years ago

Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024

Feb 2, 2024, 4:15 PM EST - 2 years ago

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Jan 18, 2024, 5:00 PM EST - 2 years ago

Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap

Jan 4, 2024, 4:45 PM EST - 2 years ago

Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023

Jan 4, 2024, 4:40 PM EST - 2 years ago

Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025

Jan 4, 2024, 4:35 PM EST - 2 years ago

Axogen Announces Promotions on Research and Development Team

Dec 26, 2023, 4:15 PM EST - 2 years ago

Axogen, Inc. Appoints Kathy Weiler to its Board of Directors

Dec 6, 2023, 7:00 AM EST - 2 years ago

Axogen Announces Transition of Finance Team Leadership

Dec 1, 2023, 5:00 PM EST - 2 years ago

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 7, 2023, 7:00 AM EST - 2 years ago

Axogen, Inc. Reports 2023 Third Quarter Financial Results

Oct 18, 2023, 7:00 AM EDT - 2 years ago

Axogen, Inc. to Report Third Quarter 2023 Financial Results and Host Conference Call on November 7, 2023

Sep 5, 2023, 7:00 AM EDT - 2 years ago

Axogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector™

Aug 31, 2023, 7:00 AM EDT - 2 years ago

Axogen to Participate at Upcoming Investor Conferences

Aug 21, 2023, 7:00 AM EDT - 2 years ago

Axogen, Inc. Begins Processing Avance® Nerve Graft at New State-of-the-Art Facility in Dayton, Ohio

Aug 7, 2023, 4:01 PM EDT - 2 years ago

Axogen, Inc. Reports 2023 Second Quarter Financial Results

Jul 27, 2023, 7:00 AM EDT - 2 years ago

Axogen to Participate at Canaccord Genuity's 43rd Annual Growth Conference

Jul 26, 2023, 7:00 AM EDT - 2 years ago

Axogen, Inc. to report second quarter 2023 financial results and host conference call on August 7, 2023

May 24, 2023, 7:00 AM EDT - 3 years ago

Axogen to Participate at Jefferies Healthcare Conference

RunnerSignals Apr. 25 at 6:12 AM

$CLSK $AMX $AXGN $INDI $SLM 3d streaks +3–7.6%, vol 1.3–3.1x, rsi high-60s

0 · Reply

dustin1101 Apr. 24 at 2:32 PM

$AXGN No significant sellers, buyers lurking. Likely coils up at ~$39 and then smashes into the $40’s. GL shorty 🤑

0 · Reply

dustin1101 Apr. 24 at 1:47 PM

$AXGN Cannacord $40 >>> $45 pt today.. sleepy stock open let's goooo!

0 · Reply

dustin1101 Apr. 23 at 2:54 PM

$AXGN just loaded back in 36.94. 2K shares. Lake Street $40 >>>$50 pt today. Still wary of mkt but ER next week...

0 · Reply

dustin1101 Apr. 22 at 4:53 PM

$AXGN selling back some over $37 since the mkt seems like it could roll over here. Not a lot of sellers though.

0 · Reply

dustin1101 Apr. 21 at 9:12 PM

$AXGN there you have it.. Easy reload on the pullback. Added 36.50 and 36.04 today. More powder available if needed.

0 · Reply

dustin1101 Apr. 20 at 2:23 PM

$AXGN Have to figure it checks out the $36-37 range again, barring another catalyst.

0 · Reply

dustin1101 Apr. 17 at 6:15 PM

0 · Reply

dustin1101 Apr. 17 at 1:37 PM

$AXGN Can't say I didn't just warn them.. 😂🤑

0 · Reply

WAJeff Apr. 17 at 1:33 PM

$AXGN $39 52 week high

0 · Reply

dustin1101 Apr. 17 at 1:25 PM

$AXGN Leerink PT $43 >>> $49

0 · Reply

StockConsultant Apr. 17 at 2:17 AM

$AXGN Axogen stock, nice top of range breakout, from Stocks to Watch, volume +193% at https://stockconsultant.com/?AXGN

0 · Reply

dustin1101 Apr. 16 at 10:49 PM

$AXGN Nice catalyst. Big chart breakout. The first of many insurers to pick up Avance IMO.

0 · Reply

notreload_ai Apr. 16 at 9:43 PM

$AXGN shares rose after $CI will cover its nerve graft from Apr 2026, helping more patients get nerve repair after surgery. https://notreload.xyz/xy/axogen-surges-as-cigna-covers-avance-nerve-graft/

0 · Reply

OpenOutcrier Apr. 16 at 8:00 PM

RECAP 4/16 Chatter: $PII + Tariffs wont affect guide $AXGN + Vgue chatter $CRWD + OpenAI trusted cyber access Live Breaking trading news www.openoutcrier.com

0 · Reply